Skip to Content

Thermo Fisher Scientific Inc TMO

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Thermo Fisher Scientific Sees Strong Performance in Q1 as Vaccines Contribute to COVID-19 Windfall

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We are maintaining our fair value estimate for wide-moat Thermo Fisher Scientific following the release of first-quarter results. The company delivered strong performance, with healthy recovery in the base business (up 13% organically), supported by $2.9 billion in COVID-19 pandemic response revenue. The shares appear fairly valued at current levels.

Read Full Analysis

Company Profile

Business Description

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).

Contact
168 Third Avenue
Waltham, MA, 02451
T +1 781 622-1000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Aggressive Growth
Employees 75,000

Related